CINECA IRIS Institutional Research Information System

RAPPOSELLI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.055
AS - Asia 7.924
EU - Europa 7.177
SA - Sud America 1.061
AF - Africa 313
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 5
Totale 32.554
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.567
IT - Italia 2.591
SG - Singapore 2.499
CN - Cina 2.301
HK - Hong Kong 1.186
SE - Svezia 1.010
DE - Germania 948
BR - Brasile 883
VN - Vietnam 675
BG - Bulgaria 518
FR - Francia 469
CA - Canada 399
TR - Turchia 374
GB - Regno Unito 318
FI - Finlandia 302
RU - Federazione Russa 253
JP - Giappone 186
AT - Austria 184
IN - India 179
UA - Ucraina 161
CI - Costa d'Avorio 96
KR - Corea 95
PL - Polonia 89
BD - Bangladesh 73
CH - Svizzera 73
NL - Olanda 69
AR - Argentina 50
BE - Belgio 46
IQ - Iraq 45
MX - Messico 43
SN - Senegal 39
SA - Arabia Saudita 38
CZ - Repubblica Ceca 37
ZA - Sudafrica 37
ES - Italia 35
ID - Indonesia 35
NG - Nigeria 33
MA - Marocco 31
PK - Pakistan 29
PH - Filippine 27
VE - Venezuela 26
UZ - Uzbekistan 25
CO - Colombia 24
EC - Ecuador 19
MY - Malesia 19
CL - Cile 18
EG - Egitto 18
IL - Israele 18
AU - Australia 17
LT - Lituania 15
JO - Giordania 14
PE - Perù 13
PY - Paraguay 12
IR - Iran 11
JM - Giamaica 11
KE - Kenya 11
NP - Nepal 10
UY - Uruguay 10
DZ - Algeria 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
AZ - Azerbaigian 8
CR - Costa Rica 8
KZ - Kazakistan 8
TH - Thailandia 8
TW - Taiwan 8
LB - Libano 7
OM - Oman 7
BJ - Benin 6
IE - Irlanda 6
KH - Cambogia 6
PA - Panama 6
RO - Romania 6
BB - Barbados 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
GR - Grecia 5
PS - Palestinian Territory 5
PT - Portogallo 5
AL - Albania 4
BO - Bolivia 4
GA - Gabon 4
GE - Georgia 4
GH - Ghana 4
LK - Sri Lanka 4
NO - Norvegia 4
AO - Angola 3
EE - Estonia 3
EU - Europa 3
HU - Ungheria 3
LV - Lettonia 3
MK - Macedonia 3
NI - Nicaragua 3
RS - Serbia 3
TT - Trinidad e Tobago 3
A1 - Anonimo 2
BH - Bahrain 2
BW - Botswana 2
CG - Congo 2
CY - Cipro 2
Totale 32.519
Salva come PNG Salva come JPEG
Città #
Ashburn 1.710
Woodbridge 1.545
Singapore 1.424
Hong Kong 1.159
Fairfield 1.046
Ann Arbor 964
Chandler 921
Houston 912
San Jose 909
Santa Clara 746
Dallas 734
Serra 675
Shanghai 591
Milan 550
Beijing 524
Sofia 518
Seattle 444
Wilmington 370
Cambridge 350
New York 330
Ottawa 308
Boardman 291
Los Angeles 246
Princeton 245
Izmir 244
Lawrence 202
Jacksonville 188
Lauterbourg 185
Medford 178
Tokyo 172
Vienna 170
Ho Chi Minh City 159
Pisa 159
Nanjing 154
Council Bluffs 149
Frankfurt am Main 129
Des Moines 128
Hefei 123
Hanoi 119
Rome 103
Chicago 100
Abidjan 96
Helsinki 94
Redondo Beach 91
Istanbul 89
London 86
Florence 84
Dong Ket 79
Munich 79
Seoul 77
Redwood City 76
Marseille 75
Dearborn 74
São Paulo 73
Warsaw 73
Nanchang 71
Buffalo 70
San Diego 62
Bern 50
Orem 50
Shenyang 48
The Dalles 46
Boulder 45
Brussels 44
Columbus 43
Dakar 39
Ogden 39
Tianjin 39
Turku 38
Nürnberg 37
Lucca 36
Norwalk 36
Hebei 35
Da Nang 34
Rio de Janeiro 34
San Francisco 34
Phoenix 33
Lagos 31
Nuremberg 31
Bremen 30
Brno 30
Carrara 30
Toronto 30
Hangzhou 28
Livorno 28
Pescara 28
Pune 28
Belo Horizonte 27
Fort Wayne 27
Changsha 26
Kunming 26
Montreal 26
Amsterdam 25
Washington 25
Genoa 24
Auburn Hills 23
Düsseldorf 23
Fuzhou 23
Jüchen 23
Paris 23
Totale 22.898
Salva come PNG Salva come JPEG
Nome #
2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS INHIBITORS OF PDK1 (US Patent App. 15/735,468, 2018) 312
Design and synthesis of 2-oxindole based multi-targeted inhibitors of PDK1/Akt signaling pathway for the treatment of glioblastoma multiforme 303
2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE COMPOUNDS AND THEIR USE AS DUAL INHIBITORS OF PDK1/AURA 300
Iminothioethers as Hydrogen Sulfide Donors: From the Gasotransmitter Release to the Vascular Effects 299
Synthesis of Novel 3,5-Disubstituted-2-oxindole Derivatives As Antitumor Agents against Human Nonsmall Cell Lung Cancer 293
A patent update on PDK1 inhibitors (2015-present) 280
Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease 252
Multifunctional Drugs: New challenging chimeras in medicinal chemistry and drug discovery 243
Locking PDK1 in DFG-out conformation through 2-oxo-indole containing molecules: Another tools to fight glioblastoma 235
Synthesis and evaluation of multi-functional NO-donor/insulin-secretagogue derivatives for the treatment of type II diabetes and its cardiovascular complications 233
Dual inhibition of PDK1 and Aurora Kinase A: an effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells 231
Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells 229
Memantine prodrug as a new agent for alzheimer’s disease 225
New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: Design,Synthesis, and Biopharmacological Properties 220
A NEW NITRIC OXIDE RELEASING ANTI-DIABETIC HYBRID DRUG: FROM THE DESIGN TO THE PHARMACOLOGICAL CHARACTERIZATION 216
Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease 214
The pleiotropic functionality of endogenous 3-iodothyronamine (T1AM) and synthetic thyronamine-like analogs: a powerful tool to target interlinked diseases such as obesity and neurodegeneration 211
Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes 209
In-vitro evaluation of new pharmacodynamic hybrids with insulin secretagogue and NO-donor activity 207
Synthesis and AT1 affinity evaluation of benzamidophenyl analogs of known AT1 receptor ligands with similar aromatic skeleton 205
Arylthioamides as H2S Donors:l-Cysteine-Activated Releasing Properties and Vascular Effects in Vitro and in Vivo 204
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 203
Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side chain, docking analysis, and biological assays for prenyl protein transferase inhibition 203
SAR study on arylmethyloxyphenyl scaffold: Looking for a P-gp nanomolar affinity 203
Enantiopure 3-(arylmethylidene)aminoxy-2-methylpropionic acids: synthesis and antiinflammatory properties 202
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands 202
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 201
Synthesis and In Vivo Imaging of N-(3-[11C]Methoxybenzyl)-2-(3-Methoxyphenyl)ethylaniline as a Potential Targeting Agent for P-glycoprotein 201
Dimer of rivastigmine and caffeic acid or ferulic acid, preparation method and drug composition thereof 200
Endogenous TH metabolite 3-iodothyronamine (T1AM) and synthetic thyronamine-like analogues SG-1 and SG-2 induce autophagy in human glioblastoma cells (U-87MG) 199
Design and synthesis of H2S-donor hybrids: A new treatment for Alzheimer's disease? 199
Oxidative stress, mitochondrial abnormalities and proteins deposition: multitarget approaches in Alzheimer's disease 198
Epibatidine: A Promising Natural Alkaloid in Health 198
Design, Synthesis, and In Vitro Evaluation of Novel 8-Amino-Quinoline Combined with Natural Antioxidant Acids 198
New Insights into Bitopic Orthosteric/Allosteric Ligands of Cannabinoid Receptor Type 2 196
Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors 194
Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors 193
Synthesis and In Vitro Characterization of Selective Cannabinoid CB2 Receptor Agonists: Biological Evaluation against Neuroblastoma Cancer Cells 190
Development of Classification Models for Identifying “True” P-glycoprotein (P-gp) Inhibitors Through Inhibition, ATPase Activation and Monolayer Efflux Assays 190
Synthesis and functional evaluation of novel aldose reductase inhibitors bearing a spirobenzopyran scaffold 189
New Insights into the Potential Roles of 3-Iodothyronamine (T1AM) and Newly Developed Thyronamine-Like TAAR1 Agonists in Neuroprotection 189
Pharmacological study on the cardiovascular activity of no-sartans, pharmacodynamic hybridsexhibiting at1-antagonist and no-donor properties 186
Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase 186
Spirocyclic Benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel 186
Dual PDK1/aurora kinase a inhibitors reduce pancreatic cancer cell proliferation and colony formation 184
Synthesis and 5-HT2A, 5-HT1Aand a1-Binding Affinities of 2-[2- Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-Hydroxy-3-(2- pyridin-2-yl-ethyl)amino]- and 2-[2-Hydroxy-3-(4-N-methylpiperazin- 1-yl)-amino]propoxybenzaldehyde-O-(substituted) Benzyl Oximes 182
ANTI-ISCHEMIC PROPERTIES OF A NEW SPIRO-CYCLIC BENZOPYRAN ACTIVATOR OF CARDIAC MITOCHONDRIAL ATP-SENSITIVE POTASSIUM CHANNELS 179
New Benzopyran-Based Openers of the Mitochondrial ATP-Sensitive Potassium Channel with Potent Anti-Ischemic Properties 179
2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties 179
Endogenous 3-iodothyronamine (T1Am) and synthetic thyronamine-like analog SG-2 act as novel pleiotropic neuroprotective agents through the modulation of SIRT6 179
Diaryl-substituted salicyl- and anthranyl-ketoximes as potential estrogen receptor ligands 178
(E)-[2-(4-Methylsulphonylphenyl)-1-cyclopentenyl-1-methyliden]-(arylmethyloxy)amines. Methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: synthesis and biological properties 177
Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents 177
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) 175
Mitochondrial Potassium Channels as Pharmacological Target for Cardioprotective Drugs 174
Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity 174
NO-Sartans: A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs 173
Targeting the upregulated PI3K-PDK1-Akt pathway: a drug discovery approach of treating cancer. 172
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs 172
Anti-ischemic properties of a new spiro-cyclic benzopyran activator of the cardiac mito-KATP channel 172
Iminothioethers as a novel class of H2S-donor: gasotransmitter release and vascular effects 171
H2S-RELEASING PROPERTIES OF NEW THIOAMIDE, IMINOTHIOETHER AND ISOTHIOCYANATE DERIVATIVES 170
Tacrine-6-Ferulic Acid, a Novel Multifunctional Dimer Against Alzheimer's Disease, Prevents Oxidative Stress-Induced Neuronal Death Through Activating Nrf2/ARE/HO-1 Pathway in HT22 Cells 169
New spiromorpholone- and spiromorpholine-benzopyrane derivatives as potential activators of mito-KATP channel 168
Synthesis of a Resveratrol Analogue with High Ceramide-Mediated Proapoptotic Activity on Human Breast Cancer Cells 168
Novel adenosine 5'-triphosphate-sensitive potassium channel ligands: a patent overview (2005 - 2010) 167
Cardiac ATP-sensitive potassium channels, a potential target for an anti-ischaemic pharmacological strategy 166
Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis 166
Classification models for the identification of P-gp inhibitors 165
Hydrogen sulfide: A worthwhile tool in the design of new multitarget drugs 165
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 162
Symbiotic approach applied to the synthesis of new agents for the treatment of Alzheimer’s disease 161
SG‐2: A SYNTHETIC ANALOG OF THYROID HORMONE METABOLITE 3‐IODOTHYRONAMINE (T1AM), PREVENTS β‐AMYLOID NEUROTOXICITY IN VITRO 161
Aryl-substituted methyleneaminoxymethyl (MAOM) analogues of diarylcyclopentenyl cyclooxygenase-2 inhibitors: effects of some structural modifications on their biological properties 160
Ceramide analogues in apoptosis: a new strategy for anticancer drug development 160
Antiarrhythmic activity of a new spiro-cyclic benzopyran activator of the cardiac mitochondrial ATP dependent potassium channels 160
Synthesis and biological evaluation of (Hetero)aryl-methyloxyphenyl derivatives as potent P-glycoprotein modulating agents. 158
Discovery of novel N-substituted carbazoles as neuroprotective agents with potent anti-oxidative activity 157
Areca catechu—From farm to food and biomedical applications 157
Targeting autophagy impairment improves the phenotype of a novel CLN8 zebrafish model 156
P-gp Transporter and its Role in Neurodegenerative Diseases 156
Novel Estrogen Receptor Ligands Based on an Anthranylaldoxime Structure: Role of the Phenol-Type Pseudocycle in the Binding Process 154
Synthesis and pharmacological evaluation of multifunctional tacrine derivatives against several disease pathways of AD 154
Synthesis and Biological Evaluation of Cyclopropylamine Vitamin D‐Like CYP24A1 Inhibitors 153
Aminobenzothiazoles as beta-Selective Estrogen Receptor Ligands 152
Conformationally restrained ceramide analogues: effects of lipophilic modifications on the antiproliferative activity 151
Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders 151
Synthesis and prostaglandin synthase inhibitory activity of new aromatic O-alkyloxime ethers substituted with methylsulfonamido or methylsulfonyl groups on their aliphatic portion 150
Multi-targeted ChEI-copper chelating molecules as neuroprotective agents 150
Synthesis, Antifungal Activity, and Molecular Modeling Studies of New Inverted Oxime Ethers of Oxiconazole 149
NO-glibenclamide derivatives: prototypes of a new class of nitric oxide-releasing anti-diabetic drugs 149
Derivati arilpiperazinici quali inibitori della Glicoproteina-P (P-gp) utili nella Multidrug Resistance (MDR) indotta da chemioterapici 148
THIOAMIDE, IMINOTHIOETHER AND ISOTHIOCYANATE DERIVATIVES: CHEMOTYPES OF SLOW H2S-RELEASING AGENTS 148
Synthesis of new potent P-glycoprotein inhibitors and their screening: potential tools to reduce the multidrug resistance 147
Classification models for the identification of P-gp inhibitors. 147
Evaluation of the NO-releasing properties of NO-donor linkers 147
New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective 147
Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis 145
Synthesis and COX2 inhibitory properties of N-Phenyl-and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene, and isoxazole analogs 145
SUN-717 SG-2 a Novel Multi-Target Directed Ligand (MTDL) for the Treatment of Neurodegenerative Diseases (NDDS) 145
Totale 18.708
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.155
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.155
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021260 0 0 0 0 0 0 0 0 0 0 0 260
2021/20222.354 33 185 69 126 379 317 89 127 72 90 142 725
2022/20233.180 382 393 218 260 323 462 19 220 617 35 162 89
2023/20242.483 323 281 277 167 337 387 137 46 29 84 92 323
2024/20256.579 55 311 136 384 553 628 718 357 644 871 695 1.227
2025/20267.778 536 897 780 575 852 730 1.339 344 533 700 370 122
Totale 33.143